37,00 €
Orphan Drugs in Epilepsy
Par : , , ,Formats :
Actuellement indisponible
Cet article est actuellement indisponible, il ne peut pas être commandé sur notre site pour le moment. Nous vous invitons à vous inscrire à l'alerte disponibilité, vous recevrez un e-mail dès que cet ouvrage sera à nouveau disponible.
Disponible dans votre compte client Decitre ou Furet du Nord dès validation de votre commande. Le format Multi-format est :
- Pour les liseuses autres que Vivlio, vous devez utiliser le logiciel Adobe Digital Edition. Non compatible avec la lecture sur les liseuses Kindle, Remarkable et Sony
, qui est-ce ?Notre partenaire de plateforme de lecture numérique où vous retrouverez l'ensemble de vos ebooks gratuitement
Pour en savoir plus sur nos ebooks, consultez notre aide en ligne ici
C'est si simple ! Lisez votre ebook avec l'app Vivlio sur votre tablette, mobile ou ordinateur :
- Nombre de pages86
- FormatMulti-format
- ISBN978-2-7420-1237-4
- EAN9782742012374
- Date de parution22/09/2011
- Protection num.pas de protection
- Infos supplémentairesMulti-Format
- ÉditeurJohn Libbey Eurotext
Résumé
More than half of epilepsies start before the age of 20 years and nearly 25% of them are refractory.
A tiny proportion of them are even labelled a "rare illness", i.e. one affecting less than 200, 000 people in the United States or less than 5 out of 10, 000 people in the European Union.
For these patients, two problems in their management arise:
In children, seizures affect an immature brain and can impact its development.
It is therefore essential to treat them so that brain development continues as normally as possible. The rarity of these syndromes does not encourage the pharmaceutical industry to invest in research. Therefore, there are few drugs available. However, a few target syndromes with a particularly unfavourable diagnosis. This work outlines 6 molecules in detail that are specifically used in epileptic encephalopathies.
Every aspect of these molecules is discussed, including drug development, indication, efficacy, cost, etc. Drafted by international experts in the field of epileptology, it provides all the necessary information on orphan drugs and their clinical use.
It is therefore essential to treat them so that brain development continues as normally as possible. The rarity of these syndromes does not encourage the pharmaceutical industry to invest in research. Therefore, there are few drugs available. However, a few target syndromes with a particularly unfavourable diagnosis. This work outlines 6 molecules in detail that are specifically used in epileptic encephalopathies.
Every aspect of these molecules is discussed, including drug development, indication, efficacy, cost, etc. Drafted by international experts in the field of epileptology, it provides all the necessary information on orphan drugs and their clinical use.
More than half of epilepsies start before the age of 20 years and nearly 25% of them are refractory.
A tiny proportion of them are even labelled a "rare illness", i.e. one affecting less than 200, 000 people in the United States or less than 5 out of 10, 000 people in the European Union.
For these patients, two problems in their management arise:
In children, seizures affect an immature brain and can impact its development.
It is therefore essential to treat them so that brain development continues as normally as possible. The rarity of these syndromes does not encourage the pharmaceutical industry to invest in research. Therefore, there are few drugs available. However, a few target syndromes with a particularly unfavourable diagnosis. This work outlines 6 molecules in detail that are specifically used in epileptic encephalopathies.
Every aspect of these molecules is discussed, including drug development, indication, efficacy, cost, etc. Drafted by international experts in the field of epileptology, it provides all the necessary information on orphan drugs and their clinical use.
It is therefore essential to treat them so that brain development continues as normally as possible. The rarity of these syndromes does not encourage the pharmaceutical industry to invest in research. Therefore, there are few drugs available. However, a few target syndromes with a particularly unfavourable diagnosis. This work outlines 6 molecules in detail that are specifically used in epileptic encephalopathies.
Every aspect of these molecules is discussed, including drug development, indication, efficacy, cost, etc. Drafted by international experts in the field of epileptology, it provides all the necessary information on orphan drugs and their clinical use.
A propos de Marina Nikanorova